20 results
424B5
IFRX
InflaRx N.V.
28 Jun 24
Prospectus supplement for primary offering
4:56pm
to the currency introduced at the start of the third stage of European economic and monetary union pursuant to the treaty establishing the European Community
6-K
EX-99.1
IFRX
InflaRx N.V.
24 Jun 24
Current report (foreign)
4:16pm
needs in critical care today, with no approved therapy, and we’re delighted to expand our dedication to the community with this study made possible
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
community activating complement and PRRs* to induce inflammatory cytokines (IL-6, IL-23) promoting Th17 cell expansion and neutrophil recruitment
6-K
EX-99.2
IFRX
InflaRx N.V.
1 Nov 23
Current report (foreign)
8:04am
among the medical community, and initiating our sales efforts.
In July 2023 and subsequently in October 2023, the National Institute of Health (NIH … community with the goal of reaching concurrence of the NIH guideline committee position with the detailed published FDA review and thus reconsidering
6-K
EX-99.3
kah 6t631
10 Aug 23
Report of Foreign Private Issuer
8:00am
6-K
EX-99.1
wulav8pe5ski
3 May 21
Current report (foreign)
4:15pm
424B5
4gma5wgr2zpsedr
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
8el1b4t1 5qoawv
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
25xc4bt0 2i
24 Feb 21
Current report (foreign)
4:16pm
424B5
w1w sfbpbx4
20 Jul 20
Prospectus supplement for primary offering
9:21am
20-F/A
476qs
29 Mar 19
Annual report (foreign) (amended)
4:23pm
6-K
EX-99.3
we3 zodcri107n0j5
21 Nov 18
Current report (foreign)
8:34am
424B4
tg8vdo68yffdsqjpi
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
mxvk8yk r93s
2 May 18
Registration statement (foreign)
7:10am
20-F
jlhdyaxjoymt90kxa
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next